EU and US could reach trade deal this weekend - Reuters
FRANKLIN LAKES, N.J. - BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology firm, has declared a quarterly dividend of $1.04 per common share. This dividend is payable on June 30, 2025, to shareholders of record as of June 9, 2025. The company’s annual dividend rate is now indicated at $4.16 per share, representing a 2.03% yield. According to InvestingPro, BD has raised its dividend for 54 consecutive years, demonstrating remarkable consistency in shareholder returns.
BD is recognized as one of the leading medical technology companies worldwide, with a substantial market capitalization of $59.35 billion and annual revenue exceeding $20.6 billion. The company is committed to advancing health by enhancing medical discovery, diagnostics, and care delivery. The company supports healthcare professionals with innovative technologies and solutions aimed at improving patient care and clinical processes. With over 70,000 employees, BD maintains a significant presence in nearly every country, partnering with various organizations to tackle global health challenges. InvestingPro analysis reveals the company maintains a strong financial health score, suggesting robust operational stability.
The company’s efforts focus on enhancing safety and efficiency for healthcare providers, enabling precise disease detection in laboratories, and supporting the development of new diagnostics and therapeutics by researchers. BD’s collaborations with customers are designed to improve health outcomes, reduce costs, and increase access to healthcare.
The dividend announcement reflects BD’s ongoing commitment to providing value to its shareholders and its confidence in the company’s financial stability. This move is consistent with BD’s history of delivering dividends to its shareholders.
For more information on BD and its initiatives, interested parties can visit the company’s website or connect through professional networking platforms.
This news is based on a recent press release statement from BD.
In other recent news, Becton, Dickinson and Company (BD) has announced plans to separate its Biosciences and Diagnostic Solutions business to enhance strategic focus and shareholder value. This decision is part of BD’s strategy to position itself as a leader in medical technology while allowing the separated business to thrive in life sciences. Additionally, BD has received 510(k) clearance from the U.S. FDA for the Phasix™ ST Umbilical Hernia Patch, marking a significant advancement in hernia repair technology with its fully absorbable design. The company also commenced a clinical trial for the GalaFLEX LITE™ Scaffold, aimed at improving outcomes in breast revision surgeries by reducing capsular contracture recurrence.
In terms of corporate governance, BD has appointed Gregory J. Hayes to its board of directors. Hayes brings extensive experience from his role as executive chairman of RTX Corporation, enhancing BD’s board as it undergoes strategic transformations. Analyst firm Piper Sandler recently adjusted its price target for BD, reducing it to $260 from $280, while maintaining an Overweight rating, citing expected operational gains in revenue and earnings. Despite challenges such as tariffs, Piper Sandler views BD’s diversified operations as a protective factor. These developments reflect BD’s ongoing efforts to innovate and adapt in a dynamic healthcare landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.